Isolation and Quantitation of a Minor Determinant of Hen Egg White Lysozyme Bound to I-A\(^k\) by Using Peptide-Specific Immunoaffinity

Raffi Gugasyan, Ilan Vidavsky, Christopher A. Nelson, Michael L. Gross and Emil R. Unanue

*J Immunol* 1998; 161:6074-6083; ;
http://www.jimmunol.org/content/161/11/6074
Isolation and Quantitation of a Minor Determinant of Hen Egg White Lysozyme Bound to I-A^k by Using Peptide-Specific Immunoaffinity

Raffi Gugasyan,* Ilan Vidavsky,† Christopher A. Nelson,* Michael L. Gross,† and Emil R. Unanue*1*

We report here the identification and quantitation of a minor epitope from hen egg white lysozyme (HEL) isolated from the class II MHC molecule I-A^k of APCs. We isolated and concentrated the peptides from the I-A^k extracts by a peptide-specific mAb, followed by their examination by electrospray mass spectrometry. This initial step improved the isolation, recovery, and quantitation and allowed us to identify 13 different minor peptides using the Ab specific for the HEL tryptic fragment 34–45. The HEL peptides varied on both the amino and carboxy termini. The shortest peptide was a 19-mer (residues 31–49), followed by the tryptic fragment encompassing residues 52–61 (6). The T cells were reactive to the core sequence 52–61 (7, 8), which bound with a relatively high affinity to I-A^k molecules (7, 9). When the peptides were isolated from APC exposed to HEL, we found a relatively large representation of peptides bearing the 52–61 epitope (10–12). These peptides were found as a nested set of long peptides centered on the 52–61 sequence, with variation on both the amino and carboxy termini (10, 11). These terminal extensions have since been shown to be of considerable importance; they contribute to the higher affinity binding of the peptide to the I-A^k and significantly extend the duration of this complex on the surface of the APC (13). Moreover, the C-terminal flanking residues have a marked effect on T cell reactivity (14). Our studies have also pointed out the limitations of defining epitopes based only on T cell responses. Epitopes previously defined as cryptic, i.e., “silent” (15), have in fact been displayed by the MHC class II molecules but have been presented in a conformation that was not recognized by some T cell clones (16, 17).

In our analysis of HEL peptides, we are concerned with the identification of those that appear to be represented to a much lesser extent than 48–62. What is the nature of these peptides, and what are their reasons for being “subdominant” or “minor”? How do we go about examining them, and what are the technologic limitations for their isolation, keeping in mind that these peptides could be those with lower affinity for MHC molecules? Indeed, it is likely that a major issue in MHC-peptide analysis is the isolation of low affinity binding peptides. Mass spectrometry analysis of MHC-bound peptides has been the technique of choice since its introduction by Hunt et al. (18). Their initial studies revealed that MHC molecules contained an abundance of peptides estimated at greater than 2000 self-peptides for the class II I-A^d (18) predominately derived from the processing of membrane and vesicular proteins (18–20). A common strategy for isolating peptides involves the separation of a heterogeneous peptide population by reverse-phase HPLC, screening each fraction with T cell hybridomas, and then identifying the peptides that trigger the T cell by mass spectrometry or Edman degradation (10, 21–23). This approach may skew the results against the weaker binding peptides for two reasons. First, each peptide may bind to APC with markedly different strengths and kinetics. Second, since each HPLC fraction consists of multiple peptides, these may compete for binding to the class II molecules on the APC. As a consequence, the T cell screen may not detect weaker binding peptides, thus favoring peptides of higher binding strength. In addition, low affinity peptides may be lost preferentially during the biochemical purification procedure.
Recently, the combined strategy of immunoaffinity chromatography and mass spectrometry analysis was employed for the characterization of peptide fragments from proteins (24–26) and for the isolation of limiting amounts of protein from complex biologic material (27, 28). We have now adapted the principle of immunoaffinity capture and developed it as a strategy to isolate low abundance class II-associated peptides. Using a monoclonal anti-peptide Ab, we recovered picomole-to-femtomole levels of HEL peptides, which were previously identified in the tryptic fragment 34–45 (29).

Materials and Methods

Cell lines

We used the murine B cell lymphoma line M12.C3.F6 transfected with a membrane form of HEL (M12-Aκ mHEL) (11). The HEL fusion protein was engineered with site-directed mutagenesis by using a procedure previously described by Brooks et al. (30). Our control cell line, M12.C3.F6, expressing class II I-κκ (M12-Aκ) (31), and M12-Aκ mHEL were cultured in DMEM supplemented with 5% FCS. The M12-Aκ mHEL process and present HEL peptides equally to M12-Aκ given exogenous HEL (11).

Production of mAbs

mAbs to HEL peptides were produced by standard hybridoma procedures. Briefly, the synthetic HEL peptide 34–45 was coupled to the carrier protein keyhole limpet hemocyanin using bromoacetyl succinimidane (Sigma, St. Louis, MO). CAF.1/1 mice (The Jackson Laboratories, Bar Harbor, ME) were first injected i.p. with peptide-hemocyanin in CFA (Sigma), followed by three i.p. injections in incomplete CFA (Sigma) at 4–6-wk intervals. Finally, 3 days before B cell fusion, the mice were boosted i.v. with 25 μg of peptide-hemocyanin in sterile PBS. Splenocytes were fused with the myeloma fusion partner P3X63.Ag8 at a ratio of 5:1. Cell fusion was induced with polyethylene glycol 1500 (Boehringer Mannheim, Indianapolis, IN) by using the standard fusion protocol.

The hybridoma supernatants were screened by an ELISA assay in which 96-well Maxisorp plates (NUNC, Roskilde, Denmark) were coated with 5 μg/ml of denatured HEL (Sigma). The positive wells were then cloned. Six Abs were found to be specific for the HEL peptide 34–45, of which VAL-3 (isotype IgG1) was used. The epitope of this Ab is on the amino terminus spanning from residues 34–38 (FESNF). VAL-3 hybridoma cells were injected into pristane (Sigma)-treated SCID mice, and the IgG1 Ab was purified from ascites using protein A-Sepharose (Sigma).

Synthesis of synthetic peptides

Peptides were synthesized by F-moc chemistry (model 432A; Applied Biosystems, Foster City, CA) and purified by reverse-phase HPLC (600E; Waters, Milford, MA). The sequences of all peptides were subsequently confirmed by mass spectrometry. For binding studies, peptides were radioiodinated (211I) on Tyr residues using the chloramine-T method (32). Each peptide was iodinated to a specific activity of 0.5 mCi/μmol of peptide.

Isolation of I-κκ-associated HEL peptides

I-κκ molecules were isolated from M12-Aκ mHEL B lymphoma cells (10) and grown to a cell density of 2 × 10^6 cells/ml to yield a total of 10^9 cells. These cells were lysed in the presence of MEGA 8/MEGA 9 detergent (Sigma) and enzyme inhibitors (PMSF, iodoacetamide, and leupeptin) as described (10). The I-κκ molecules were isolated by immunoaffinity chromatography using the anti I-κκ Ab 40F (33). The peptides were subsequently released by acid treatment. In the experiment shown in Fig. 1, each peptide was separated by conventional reverse-phase HPLC (600E; Waters). Each 250-μl fraction was tested in a T cell bioassay using either the T cell hybridoma A6A2, which is specific for the core sequence 52–61, or A6A2, which recognizes the tryptic fragment 34–45 (29, 34). Added to each well were 10^5 T cells and 5 × 10^4 APCs (M12-Aκ) in a total volume of 200 μl. After 18 h, the supernatant was tested for the presence of IL-2 using the IL-2-dependent cell line CTTL. The fractions with detectable levels of IL-2 were dried down and reconstituted with a 5% acetonitrile, 0.5% trifluoroacetic acid (TFA) solution. The fractions were then pooled and analyzed by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) or tandem mass spectrometry.

For the isolation of peptides by peptide-specific immunoaffinity, we used lysates from 10^9 M12-Aκ mHEL cells. The procedure consisted of five consecutive steps: 1) capture of the I-κκ molecules using 40F Ab (40F binds to all I-κκ molecules), 2) release of peptides bound to I-κκ, 3) capture of the peptide by the Ab to 34–45, 4) release of the peptide, and 5) analysis of the peptide by mass spectrometry. Specifically, the cell lysate was incubated for 2 h at 4°C with the Ab 40F coupled to cyanogen bromide-activated Sepharose beads (Sigma). Next, the material was loaded into a disposable 14-cm PolyPrep chromatography column (Bio-Rad, Hercules, CA) and washed with at least 20 column volumes of wash buffer (20 mM MEGA 8/MEGA 9 in PBS). The I-κκ peptide complexes were subsequently eluted with 0.1% TFA, causing the simultaneous dissociation of this complex. The free peptide mixture was neutralized with 1 M Tris, pH 7.4, and then passed through a Centricron-10 concentrator (Amicon, Beverly, MA) to exclude the high molecular mass material. In a second chromatography step, this mixture was incubated with VAL-3 coupled to cyanogen bromide-activated Sepharose beads (Sigma). Next, the material was loaded into a disposable 14-cm PolyPrep chromatography column (Bio-Rad, Hercules, CA) and washed with at least 20 column volumes of wash buffer (20 mM MEGA 8/MEGA 9 in PBS). The I-κκ peptide complexes were subsequently eluted with 0.1% TFA, causing the simultaneous dissociation of this complex. The free peptide mixture was neutralized with 1 M Tris, pH 7.4, and then passed through a Centricron-10 concentrator (Amicon, Beverly, MA) to exclude the high molecular mass material. In a second chromatography step, this mixture was incubated with VAL-3 coupled to cyanogen bromide-activated Sepharose beads (Sigma). Next, the material was loaded into a disposable 14-cm PolyPrep chromatography column (Bio-Rad, Hercules, CA) and washed with at least 20 column volumes of wash buffer (20 mM MEGA 8/MEGA 9 in PBS). The I-κκ peptide complexes were subsequently eluted with 0.1% TFA, causing the simultaneous dissociation of this complex. The free peptide mixture was neutralized with 1 M Tris, pH 7.4, and then passed through a Centricron-10 concentrator (Amicon, Beverly, MA) to exclude the high molecular mass material.
was dried down; reconstituted in a total volume of 80 μl of a 2% acetonitrile, 0.6% acetic acid solution; and then pooled. The sample was subsequently subjected to tandem mass spectrometry.

**Analysis by mass spectrometry**

For MALDI-TOF mass spectrometry analysis, 0.5 μl of the sample (from the standard method) was mixed with 0.5 μl of the MALDI matrix solution 4-hydroxycyanocinnamic acid (Hewlett-Packard, Chicago, IL) on the matrix plate. MALDI-TOF analysis was performed in the linear mode on a PerSeptive Voyager-RP Reflection instrument (PerSeptive Diagnostics, Framingham, MA) using the Voyager and GRAMS/386 software. The accelerating voltage was 25–30 kV, and the ions were desorbed by an N2 laser at 1 = 337 nm with a 3-nls pulse width.

Samples from many of the experiments were subjected to capillary reverse-phase HPLC mass spectrometric analysis. Using the Rheodyne 7125 injector, we injected 15 μl of the prepared sample into the reverse-phase HPLC, which consisted of a Zorbax C18 0.3-mm × 25-cm column (MicroTech, Sunnyvale, CA). Conditions of the gradient were as follows: solvent A (6% acetic acid in water) was kept constant at 10%; solvent B (acetonitrile) was kept constant at 2% for the first 5 min, increased from 2 to 15% in the next 5 min, and then increased from 15 to 90% at a rate of 0.9%/min; and solvent C (water) maintained the mixture at 100% while the eluent flow rate was maintained at 4.5 μl/min. The HPLC pump was a Waters 600MS equipped with pulse damping (silk board). The flow from the pump was split by using the LC packing accurate splitter with a 0.3-mm-wide column calibrator (LC Packing, San Francisco, CA). The total column effluent was then directed at the mass spectrometer.

Peptides were identified by mass and sequenced on a Finnigan liquid chromatography quadruple ion-trap mass spectrometer (Finnegan, San Jose, CA) (i.e., in the MS and MS/MS modes, respectively). For MS mode, the scan range was at a mass-to-charge ratio (m/z) of 600-1300 in the profile mode, in which every three microscans were averaged to one scan. Acquisition was started 10–15 min after the commencement of the LCQ run. For MS/MS mode, the scan range was m/z 250-1850, again in profile mode, in which every three microscans were averaged to one scan. The parent ion was isolated with a mass window that was 2 m/z wide, and the collision energy was 25% of the maximum energy. Sequence analysis was performed by comparing the experimental ion mass with the calculated ion mass or by an automated protein database sequencing program (SEQUEST; John Yates, University of Washington, Seattle, WA) on an ICIS workstation (Finnegan).

**Peptide-I-A^k binding strength assay**

Detergent-solubilized I-A^k, purified from the T2-A^k cell line (provided by Dr. P. Cresswell, Yale University School of Medicine New Haven, CT) by affinity chromatography, was incubated with a radioactively labeled reference peptide (125I-labeled YEDYGILQINSR), a high affinity binder to I-A^k (35). The amount of peptide required to compete out 50% of this reference peptide was determined by adding known amounts of unlabeled test peptide (35). The amount of peptide required to compete out 50% of this reference peptide was determined by adding known amounts of unlabeled test peptide. Each reaction contained 10 μl of test peptide at different dilutions, 0.25 pmol of 125I-reference peptide, and 25 pmol of purified I-A^k. After incubating at room temperature for 72 h, the peptide-I-A^k complex was separated from free peptide by spinning the material through a Bio-Spin P6 gel column (Bio-Rad). The elution profile was used to identify the position of peptide-I-A^k complexes. The eluent flow rate was maintained at 4.5 μl/min. The HPLC pump was a Waters 600MS equipped with pulse damping (silk board). The flow from the pump was split by using the LC packing accurate splitter with a 0.3-mm-wide column calibrator (LC Packing, San Francisco, CA). The total column effluent was then directed at the mass spectrometer.

**SDS stability of peptide I-A^k complexes**

The strength of a peptide-MHC complex was also measured by its resistance to denaturation to SDS when run in SDS-PAGE (36, 37). Briefly, the peptides were radioactively labeled (125I) and incubated with purified I-A^k for 48 h at room temperature. The complex was resolved by immunoprecipitation using the 40F Ab at a final concentration of 25 μg/ml. The samples were resolved on a 12% SDS polyacrylamide gel. As observed by autoradiography, the peptides remaining bound to the αβ dimer migrated to the top of the gel (SDS-stable peptides), while the dissociated peptides were found at the lower segment of the gel (SDS-unstable peptides). These images were scanned by a PhosphorImager (425E, Molecular Dynamics, Sunnyvale, CA) to determine the relative proportion of SDS-stable complex.

**RESULTS**

**A second HEL determinant from I-A^k molecules**

Previous studies from our laboratory identified T cells directed to a trypic fragment of HEL encompassing residues 34–45 (29). The sequence of peptide 34–45 is Phe-Glu-Ser-Asn-Phe-Asn-Thr-Gln-Ala-Thr-Asn-Arg. The T cell response to this epitope in HEL-immunized mice was weaker, in comparison with the response of the dominant epitope 48–62. Moreover, peptide 34–45 was a weaker binder to I-A^k (29). Therefore, our initial impression was that the 34–45 epitope was subdominant or minor.

Using our standard method for peptide isolation, we found the natural form of the 34–45 peptide difficult to isolate from APC exposed to HEL. (The standard method consists of an analysis of peptides extracted from I-A^k by reverse-phase HPLC. Fractions that score positive in the T cell assay are then examined by mass spectrometry.) Earlier experiments that had been successful in isolating and characterizing the major epitope 48–62 failed to detect the 34–45 peptide (10). Two of three recent experiments revealed weak activity for the 34–45 HEL determinant. These results now are described so that a comparison can be made with the peptide immunosioization method.

Class II I-A^k molecules were purified from 1010 M12-A^k mHEL cells. By acid treatment, the complex mixture of peptides was released and then fractionated by reverse-phase HPLC. Each fraction was screened by the T-cell hybridoma 3A9 to identify the HEL peptides consisting of the core region 52–61. These peptides were identified at retention times of 72 and 78 min (Fig. 1A). In accordance with our previous observations, analysis by MALDI-TOF mass spectrometry revealed two prominent peptides, 48–62 and 48–63 (data not shown); these peptides were shown to have relative yields of 32 and 56%, respectively (10–12). In addition, each HPLC fraction was screened with the T cell hybridoma A6A2 that recognizes an epitope in the trypptic fragment 34–45. Five fractions with a retention time of 48 min showed detectable levels of IL-2, thus providing evidence for a second HEL determinant (Fig. 1A).

It is important to note that we required 36% (or 90 μl) of each fraction to detect significant levels of IL-2 for this epitope, whereas only 4% (10 μl) was required to detect the major HEL epitope 48–62.

MALDI-TOF mass spectrometry analysis of the A6A2-positive fractions revealed no prominent peaks. Two weak signals with masses of 1814.6 and 1916.3 were comparable with the theoretical peptide masses, 1813.4 and 1914.4, corresponding to the HEL peptides 31–46 and 31–47, respectively (Fig. 1B). Clearly, the signals of the two peptides were too weak to incur any confidence in these masses.

We adjusted our approach by subjecting the T cell-positive fractions to the reverse-phase HPLC online and, this time, to the electrospray mass spectrometer, to improve the resolution of the peptide samples. Doubly charged ions [M + 2H]^2+ were observed for the dominant HEL peptides that triggered the 3A9 T cell. Fig. 2A shows the m/z of 863 and 913, which corresponded to two members of this family, 48–62 and 47–62, respectively. In addition, the [M + 2H]^2+ ions of 907.92^+ and 957.7^+ represented the minor HEL peptides 31–46 and 31–47, which stimulated the A6A2 T cell hybridoma. Ions to other minor HEL peptides were evident, such as the 1043.3^+ ion (residues 31–49) (Fig. 2A). Thus, our initial MALDI-TOF results were confirmed. However, the abundance of these ions was still too weak among prominent contaminating peptides and thus difficult to analyze.
Using this last approach, we compared the recovery of the 31–47 peptide to the dominant HEL peptide 48–62. The abundances of these two naturally processed peptides were determined by electrospray mass spectrometry, comparing the amount recovered with known concentrations of synthetic peptide that were injected into the electrospray mass spectrometer. Fig. 3 shows a linear calibration curve of the 48–62 and 31–47 standard synthetic peptides. By determining the area of each ion chromatogram for the naturally processed HEL peptides 48–62 and 31–47 (Fig. 2B), the concentration of the recovered peptide was interpolated from the calibration curve. In the same experiment, the quantity of 48–62 peptide was 22.1 pmol compared with 1.01 pmol for the 31–47 peptide, indicating that the display of the 31–47 peptide was at least 22-fold lower than that of the 48–62.
FIGURE 4. Identification of a minor HEL epitope by peptide-specific immunoaffinity. Class II I-A<sup>k</sup> molecules were purified from 10<sup>9</sup> B lymphoma cells. The associated peptides were released with 0.1% TFA, and HEL peptides containing the epitope FESNF were concentrated with the mAb VAL-3. The HEL peptides were injected into the reverse-phase HPLC online to the electrospray mass spectrometer, and mass spectra were acquired after 10 min. A. The m/z range of 600-1300 revealed no detectable HEL peptides from M12-A<sup>k</sup> cells. B. In M12-A<sup>k</sup> mHEL, doubly charged [M + 2H]<sup>2+</sup> ions ranging from 779<sup>2+</sup> to 1043.8<sup>2+</sup> were detected. Thirteen of these ions corresponded to HEL peptides (Table I), of which the two most abundant ions, 907<sup>2+</sup> and 957<sup>2+</sup>, corresponded to 31–46 and 31–47, respectively. Total ion chromatograms (TIC) are shown for the peptides eluted from M12-A<sup>k</sup> (C) and M12-A<sup>k</sup> mHEL (D) (note scale change). HEL peptides are eluted at 17.7, 18.0, and 18.2 min. Reconstructed chromatograms for the [M + 2H]<sup>2+</sup> ions 850.0<sup>2+</sup>, 907.2<sup>2+</sup>, 957.7<sup>2+</sup>, 1015.1<sup>2+</sup>, and 1043.8<sup>2+</sup> correspond to the 31 series of HEL peptides.
Isolation of the 31–47 HEL determinant by peptide-specific immunoaffinity

To improve the analysis of the 31–47 HEL epitopes, we developed an approach involving peptide-specific immunoaffinity chromatography. Class II I-A<sup>k</sup> molecules were purified from the lysates of M12-A<sup>k</sup> mHEL cells and from control M12-A<sup>A</sup> cells. The peptides associated with I-A<sup>k</sup> molecules were released by acid treatment, and HEL peptides were isolated by immunoaffinity capture using the Ab VAL-3 directed to the 34–45 peptide. These fractions were pooled and injected into the reverse-phase HPLC online to the electrospray mass spectrometer. Analysis of the peptide material isolated from the B lymphoma line expressing I-A<sub>k</sub> showed no detectable peptides (Fig. 4A). By marked contrast, analysis of the peptides recovered from the M12-A<sup>k</sup> mHEL cell line revealed an array of [M + 2H]<sup>2+</sup> ions ranging from a m/z of 779.0 to 1043.8 (Fig. 4B); 13 of these ions had masses corresponding to HEL peptides (Table I). The sequences of these peptides were confirmed by MS/MS analysis, which was performed on 10 of 13 peptides. An example of the collision-activated dissociation performed on the parent ions 907.2<sup>2+</sup> and 957.7<sup>2+</sup> is shown in Fig. 5. Furthermore, a search conducted in the protein sequence database, using the SEQUEST program, identified these sequences as HEL peptides.

Five peptides were identified starting with residue 31 (alanine) but differing at their carboxy terminus, ending at residue 45, 46, 47, 48, or 49. The two most abundant ions, 907.2<sup>2+</sup> and 957.7<sup>2+</sup>, were specific to HEL peptides 31–46 and 31–47 (Fig. 4B). In addition, we identified eight other peptides, four of which started at position 32 (alanine) and four of which started at position 33 (lysine). These peptides had the same variation at the carboxy terminus as those observed with the peptides beginning at position 31. In three experiments, we did not detect the peptides 32–48 or 33–46 (see Discussion). The shortest peptide isolated was a 13-mer (residues 33–45) corresponding to the ion 779.0<sup>2+</sup>, while the longest peptide was a 19-mer (residues 31–49) with an m/z of 1043.8<sup>2+</sup>.

Analysis of the total ion chromatogram from M12-A<sup>k</sup> mHEL shows the elution of HEL peptides at 17.7, 18.0, and 18.2 min (Fig. 4D). These elution times are specific for the peptides starting at position 33, 32, and 31, respectively. Based on the m/z of each ion, the total ion chromatogram was reconstructed for each HEL peptide (an example is provided in Fig. 4D). By contrast, the total ion chromatograms of M12-A<sup>A</sup> showed no corresponding HEL peptides (Fig. 4C).

Quantitation of HEL peptides extracted from I-A<sup>k</sup> molecules

We determined the recovery of peptides during the early steps of isolation and then attempted to quantitate them. First, the 125I-labeled HEL peptide 31–47 was incubated with purified class II I-A<sup>k</sup> for 48 h at room temperature. The 125I-labeled 31–47 complex was separated from free peptide and added to the cell lysate. The relative amount of peptide recovered after each step is shown in Table II. Thus, we estimated the peptide recovery to be about 50%.

Second, we were concerned that the more weakly binding 31–47 peptide might endure a preferential greater loss during the purification of I-A<sup>k</sup>. We addressed this issue by contrasting the recovery of 125I-labeled 31–47 peptide to the more strongly binding 125I-labeled 48–61 peptide. The peptides were incubated with purified class II I-A<sup>k</sup> molecules for 48 h, and then the complexes were isolated from free peptide by centrifugation through a BioSpin P6 gel filtration column. The complexes were added into the cell lysate and recovered from an anti-class II immunoaffinity chromatography column. In accordance with the results described above, the eluted material consisted of 42% 125I-labeled 31–47 peptide compared with 31% 125I-labeled 48–61. Thus, during the isolation of I-A<sup>k</sup>, there were no preferential losses of the 31–47 more weakly binding peptides.

We also examined the efficiency of our VAL-3 immunoaffinity column. Ten picomoles of synthetic 31–47 peptide in pH-neutralized 0.1% TFA solution was incubated with 500 µl of a 50% VAL-3-cyanogen bromide-activated Sepharose slurry (250-µl bed volume). The peptide was eluted, and the analysis was performed by MALDI-TOF mass spectrometry. A recovery of 77% was quantitated by comparing the abundance of the 31–47 peptide with our reference peptide (AAKFDSNFNTQASNRNT), which was added at 0.25 pmol/µl. Overall, the peptide recovery by the anti-peptide purification strategy before the mass spectrometry analysis was estimated to be 35%.

Finally, the naturally processed HEL peptides were recovered by peptide-specific immunoaffinity and quantitated by electrospray mass spectrometry. A calibration curve was generated for four sequence-specific synthetic peptides (residues 31–47, 32–47, 33–49, and 31–46) by injecting known amounts into the reverse-phase HPLC online to the electrospray mass spectrometer (Fig. 6). Using the same conditions as those for the standard peptides, we obtained ion chromatograms for each naturally processed HEL peptide (an example is provided in Fig. 4D) and calculated the area under each

Table I. Recovery of naturally processed peptides from membrane HEL B-lymphoma line

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Observed Ions</th>
<th>Calculated&lt;sup&gt;a&lt;/sup&gt; Mass [M&lt;sup&gt;+&lt;/sup&gt;]</th>
<th>Theoretical Mass [M&lt;sup&gt;+&lt;/sup&gt;]</th>
<th>Fragment</th>
<th>Sequence</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>850.1</td>
<td>1698.2</td>
<td>1698.8</td>
<td>31–45</td>
<td>AAKFESNFNTQATNR</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>907.2</td>
<td>1812.4</td>
<td>1812.9</td>
<td>31–46</td>
<td>AAKFESNFNTQATNRN</td>
<td>16</td>
</tr>
<tr>
<td>3</td>
<td>957.7</td>
<td>1913.4</td>
<td>1913.9</td>
<td>31–47</td>
<td>AAKFESNFNTQATNRNT</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>1015.1</td>
<td>2028.2</td>
<td>2028.9</td>
<td>31–48</td>
<td>AAKFESNFNTQATNRNTD</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td>1043.8</td>
<td>2085.6</td>
<td>2086.0</td>
<td>31–49</td>
<td>AAKFESNFNTQATNRNTDGD</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>814.3</td>
<td>1626.6</td>
<td>1627.8</td>
<td>32–45</td>
<td>AKFESNFNTQATNR</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>871.9</td>
<td>1741.8</td>
<td>1741.8</td>
<td>32–46</td>
<td>AKFESNFNTQATNRN</td>
<td>15</td>
</tr>
<tr>
<td>8</td>
<td>922.1</td>
<td>1842.2</td>
<td>1842.9</td>
<td>32–47</td>
<td>AKFESNFNTQATNRNT</td>
<td>16</td>
</tr>
<tr>
<td>9</td>
<td>1008.1</td>
<td>2014.2</td>
<td>2014.9</td>
<td>32–49</td>
<td>AKFESNFNTQATNRNTD</td>
<td>18</td>
</tr>
<tr>
<td>10</td>
<td>779.0</td>
<td>1556.0</td>
<td>1556.8</td>
<td>33–45</td>
<td>KFESNFQATNR</td>
<td>13</td>
</tr>
<tr>
<td>11</td>
<td>836.1</td>
<td>1670.2</td>
<td>1670.8</td>
<td>33–46</td>
<td>KFESNFQATNRN</td>
<td>14</td>
</tr>
<tr>
<td>12</td>
<td>886.9</td>
<td>1771.8</td>
<td>1771.8</td>
<td>33–47</td>
<td>KFESNFQATNRNT</td>
<td>15</td>
</tr>
<tr>
<td>13</td>
<td>972.6</td>
<td>1943.2</td>
<td>1943.9</td>
<td>33–49</td>
<td>KFESNFQATNRNTD</td>
<td>17</td>
</tr>
</tbody>
</table>

<sup>a</sup> Calculated mass = ([M + 2H]<sup>2+</sup> × 2) – 2.

---

The Journal of Immunology
6079

Downloaded from http://www.jimmunol.org/ by guest on July 16, 2017
FIGURE 5. Sequence analysis of the naturally processed HEL peptides. Collision-activated dissociation was performed on the [M + 2H]^{2+} ions at an m/z of 907.2^{2+} (residues 31–46) (A) and 957.7^{2+} (residues 31–47) (B) using the Finnigan LCQ ion trap mass spectrometer. The sequence was acquired by comparing the observed masses of the y and b ions with those of the corresponding theoretical ions. Note that the following ions are not shown to scale: b_{16}^{2+} (A) and 958.4^{2+} and b_{17}^{2+} (B).
immunodominant HEL 48 – 61 peptide had an RIC2 isolated from the mAb VAL-3 were dried down and reconstituted in a total 47, and 33– 47 were derived as described in Fig. 3. The HEL peptides Calibration curves (squares) primarily attributed to the Asp 52 anchoring residue (35, 38). SDS FIGURE 6. peptide (RIC2) were incubated with 50 pmol of purified I-Aκ. The complex was separated by centrifugation through a Bio-spin P6 gel filtration column after 48 h. The I-Aκ purification protocol was followed. The peptide-Aκ complex was spiked into 6 ml of cell lysate from the M12-Aκ B lymphoma line. At each step, samples were counted using the gamma counter to determine the percentage of peptide recovered.

The most abundant HEL peptides, 31–47 and 31–46, were recovered at 1.3 pmol and 1 pmol, respectively (Table III). By comparison, the HEL peptide, 32–45 (4 fmol) had a 300-fold lower abundance. Interestingly, in every case the most abundant were the peptides ending at position 46 with asparagine, or at position 47 with threonine. The overall peptide recovery was 4 pmol from 109 cells.

Characterization of the subdominant HEL peptide 31–47 to I-Aκ

Our current binding studies were performed using the most abundant HEL determinant, 31–47, instead of 34–45, which was studied previously (29). Binding strength assays against the reference peptide (RIC1) revealed the HEL 31–47 peptide to be a 30-fold weaker binder (RIC1) (30) (Fig. 7A). By comparison, the immunodominant HEL 48–61 peptide had an RIC1 of 1.8, primarily attributed to the Asp121 anchoring residue (35, 38). SDS stability is a measure of the ability of a peptide to bind strongly to the class II αβ dimer. While the immunodominant HEL peptide 48–61 was 97% SDS stable, the minor 31–47 peptide ran virtually 100% SDS unstable (Fig. 7B).

Discussion

We isolated a family of peptides from HEL, of which the most abundant (residues 31–47) is about 22-fold less abundant than the dominant 48–62 peptides. These peptides also have considerably less binding strength for the I-Aκ. The analysis of the 31–47 peptides indicates the many problems with the isolation and quantification of class II MHC bound peptides, which can be resolved by the method of peptide immunofluorescence quantification. In brief, the problems with peptide isolation from class II molecules stem from the fact that a wide range of peptides with varying degrees of affinities, lengths, and compositions binds to them. This is in contrast to those that bind class I, in which there appears to be a more restricted set of peptides with regard to all of these parameters. Class I bound peptides tend to consist of 8–10 residues and to be of high affinity and with strict restrictions in their use of anchoring residues. The assays for class II peptide analysis that are now in place, which combine T cell responses and chemical analysis, by necessity introduce a strong bias against low affinity binding peptides. These peptides in complex mixtures are required to be at a higher molar concentration (for the T cell assay) and could be competed

![Image](http://www.jimmunol.org/)

**FIGURE 6.** Quantitation of the minor HEL peptides presented by I-Aκ. Calibration curves (squares) for the synthetic peptides 31–46, 31–47, 32–47, and 33–47 were derived as described in Fig. 3. The HEL peptides isolated from the mAb VAL-3 were dried down and reconstituted in a total volume of 80 μl of 2% acetonitrile, 0.6% acetic acid. Using the same conditions for generating the calibration curve, we injected 19% (15 μl) of this sample into the electrospray mass spectrometer and obtained ion chromatograms for the 13 HEL epitopes shown in Fig. 4B, an example of which is shown in Fig. 4D. The amounts of four naturally processed peptides (shaded symbols) were interpolated from sequence-specific calibration curves, while the remaining peptides were interpolated from the calibration curve of the synthetic peptide most closely resembling the naturally processed ones.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Peptide Recovery (fmol)</th>
<th>Total Estimated Content (pmol)</th>
<th>Relative Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>31–45†</td>
<td>40</td>
<td>114</td>
<td>0.96</td>
</tr>
<tr>
<td>31–46</td>
<td>947</td>
<td>2,705</td>
<td>22.7</td>
</tr>
<tr>
<td>31–47**</td>
<td>1,273</td>
<td>3,637</td>
<td>30.5</td>
</tr>
<tr>
<td>31–48**</td>
<td>74</td>
<td>211</td>
<td>1.8</td>
</tr>
<tr>
<td>31–49**</td>
<td>261</td>
<td>746</td>
<td>6.3</td>
</tr>
<tr>
<td>32–45†</td>
<td>4</td>
<td>11</td>
<td>0.1</td>
</tr>
<tr>
<td>32–46</td>
<td>222</td>
<td>634</td>
<td>5.3</td>
</tr>
<tr>
<td>32–47†</td>
<td>200</td>
<td>571</td>
<td>4.8</td>
</tr>
<tr>
<td>32–49†</td>
<td>47</td>
<td>134</td>
<td>1.1</td>
</tr>
<tr>
<td>33–45*</td>
<td>126</td>
<td>360</td>
<td>3.0</td>
</tr>
<tr>
<td>33–46*</td>
<td>418</td>
<td>1,194</td>
<td>10.0</td>
</tr>
<tr>
<td>33–47†</td>
<td>382</td>
<td>1,091</td>
<td>9.2</td>
</tr>
<tr>
<td>33–49†</td>
<td>177</td>
<td>506</td>
<td>4.2</td>
</tr>
<tr>
<td>Total</td>
<td>4,171</td>
<td>11,917</td>
<td>100</td>
</tr>
</tbody>
</table>

*Peptides were quantitated by mass spectrometry as described in Results. The amount of each naturally processed peptide was interpolated from four standard synthetic peptides, 31–46, 31–47, 32–47, 33–47. The recovery of each peptide was estimated to be 35%. The amount of class II I-Aκ purified was determined by the Folin-Ciocalteu protein assay to be 2.4 × 106 molecules per APC, in accordance with recent direct estimates on cells (41). From this estimate and knowing the content of 11.9 pmol/109 cells, we concluded that 0.3% of the I-Aκ molecules were occupied by the 31–47 series peptides. The purity of I-Aκ was estimated to be 96% when resolved on a 12% SDS-polyacrylamide gel.
T cell assay, has now been eliminated. There is considerable loss of peptides, as others have noted (39, 40), when we involve a first step of HPLC separation offline from the mass spectrometer (Figs. 1 and 2). For example, the recovery of 31–47 was 1.01 pmol per 10^10 cells (Fig. 2B) compared with the immunoaffinity capture procedure that yielded 12 pmol (in Fig. 6, we estimated a recovery of 1.2 pmol/10^9 cells) (i.e., about 92% of this peptide was lost during the initial analysis). Our estimates of occupancy of M12 C3.F6 (an APC very rich in I-A^k, about 1–2 × 10^6 sites per cell) with the 31–47 series peptide was about 0.3%. In our previous studies we estimated an occupancy with the 48–62 series of 6–9% (41). In summary, the immunoaffinity step bypasses the T cell assay, serves to concentrate the peptides, and permits a more reliable analysis and quantitation. We believe the use of a peptide immunoaffinity procedure will make it considerably easier to identify the whole spectrum of MHC-selected peptides from a known protein.

One factor that may determine the low representation of 31–47 peptides may be their affinity for I-A^k. In our analysis of HEL peptides, the most frequently displayed peptides bound to either I-A^k or I-E^k are those with high binding strength (9). Also, in the analysis of self-peptides bound to I-A^k, none is represented to the extent of 48–62, but neither do any of them display the high binding strength of 48–62. Nevertheless, more extensive analysis should tell us how strict the relationship is between extent of peptide display and binding strength for class II molecules. Concerning the 31–47 peptide, in ongoing studies we have been able to identify a major anchoring residue, Asn^39, as well as residues that hinder the binding. Whether Asn^39 fits into the P1 pocket of I-A^k (38) is not clear at present. Structural analysis of this peptide-I-A^k complex is in progress.

The family of 31–47 peptides, like many class II peptides, was displayed as a series varying in amino and carboxy termini. Here, the predominant species (about 53%) started at residue 31, ending at either 46 or 47. Our interpretation of the reasons for these nested peptides lies in the nature of the processing event. Our data lead us to believe that HEL is first denatured, allowing the opened molecule to interact with I-A^k molecules. I-A^k molecules select the segments of HEL bearing the higher affinity sequences. Once bound, the segment is protected from catabolism but is then trimmed by amino- and carboxypeptidases. Trimming extends to the edges of the combining site but is somewhat variable, leaving ends of different size. Our data are supported by experiments in which the addition of proline to the flanking residues of HEL-dominant peptide resulted in extensions of the peptide (11). We favor this scenario over other possibilities, such as an initial cutting of the molecule by cathepsins with subsequent selection of peptides. With this in mind, it is likely that presentation of the dominant segment, 48–62, may hinder the presentation of the 31–47 segment. We can conclude that at least 13% of the HEL molecules of the molecule by cathepsins with subsequent selection of peptides. With this in mind, it is likely that presentation of the dominant segment, 48–62, may hinder the presentation of the 31–47 segment. We can conclude that at least 13% of the HEL molecules

Acknowledgments

We thank Ms. Shirley Petzold for technical assistance, Ms. Mary Walton for proofreading the manuscript, and Ms. Janet Casmaer for preparation of the manuscript.

References


